Company Overview
Firefly Neuroscience, Inc. operates as a medical technology and artificial intelligence entity dedicated to delivering neuroscientific solutions designed to enhance brain health outcomes for patients suffering from mental illnesses and neurological disorders. The company's core offering, Brain Network Analytics, is a specialized software platform that focuses on diagnostic capabilities within the complex field of neuroscience. This business model places the firm squarely within the Technology sector and the Software - Application industry, positioning it to leverage advancements in artificial intelligence to address critical healthcare challenges. Currently, the company maintains a market capitalization of $34.26M and reports annual revenue of $783,000 based on trailing twelve-month data, employing a workforce of 13 individuals. These financial figures indicate that Firefly Neuroscience is an early-stage micro-cap entity, where the significant disparity between its market valuation and revenue suggests a high risk profile typical of companies prioritizing long-term R&D and market penetration over immediate profitability. The small employee count relative to the software industry standard further underscores the nascent stage of the organization's operational scale.
Financial Health
The company reported revenue of $783,000 for the trailing twelve months, yet this top-line growth is offset by a net income loss of $-25,597,000 and an EBITDA of $-8,652,000. The substantial gap between the minimal revenue and the massive net income loss reveals an extremely aggressive cost structure where operating expenses far exceed all income generated. Furthermore, the company generated negative free cash flow of $-4,214,125, which indicates a lack of financial flexibility and a heavy reliance on external capital sources to fund operations. Margin analysis shows a gross margin of 65.9%, suggesting efficient production or service delivery costs relative to revenue, but this is contrasted by an operating margin of -632.5% and a profit margin of 0.0%. The deeply negative operating margin confirms that overhead costs, such as research and development or administrative salaries, are consuming the entire revenue stream before reaching the bottom line. Regarding liquidity, the company holds $4.33M in cash while holding N/A for debt, resulting in a debt-to-equity ratio of N/A. The absence of recorded debt suggests the balance sheet is currently leveraged through equity rather than liabilities, though the cash position must support continued burn rates. The current ratio stands at 2.00, indicating that the company possesses twice the current assets necessary to cover its short-term liabilities, which points to adequate short-term liquidity despite the operational losses. Return on equity is calculated at -340.8% and return on assets at -61.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in the pursuit of product development goals.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A and the Forward P/E is also N/A, reflecting the absence of earnings; this absence implies that future earnings trajectories are entirely dependent on the successful commercialization of their neuroscientific solutions rather than current operational performance. The price-to-book ratio is 3.04, which indicates that the market values the company at more than three times its net asset value, suggesting a premium assigned to the company's intangible assets and future potential despite current losses. For valuation context, the price-to-sales ratio is 43.75 and the EV/EBITDA is -2.90; these alternative metrics suggest that investors are pricing the stock based on revenue multiples and enterprise value adjustments rather than profitability, a common practice for pre-revenue or loss-making biotech and tech firms. The 52-week high is $5.10 and the 52-week low is $0.62, placing the current market dynamics within a volatile range where the stock has experienced significant expansion from its lowest point. The beta value is N/A, meaning that standard volatility metrics relative to the broader market are not available or applicable for this specific small-cap stock. Consequently, the valuation appears disconnected from traditional profitability benchmarks, relying heavily on qualitative factors such as intellectual property and clinical pipeline progress.
Growth & Income
Revenue growth year-over-year is recorded at 1075.8%, while earnings growth year-over-year is N/A due to the company's consistent losses; this dynamic implies that the company is prioritizing top-line expansion through sales volume or market share capture rather than immediate profitability improvements. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate for sustainability, as the payout ratio is 0.0%. This non-dividend status indicates that the company reinvests all available earnings—or rather, all available cash flow—back into research, development, and business operations to fuel future growth rather than distributing capital to shareholders. The overall growth and income profile is characterized by explosive revenue expansion paired with significant financial losses and no current income distribution, typical of high-growth, pre-profitability technology firms.